Introduction:

The PML-ATO protocol for the treatment of promyelocytic leukemia has obtained excellent results, achieving high overall survival rates and the possible healing of patients. Two cardiotoxic drugs are used in the induction process: anthracyclines and arsenic trioxide, whereas during consolidation patients receive a high dose of arsenic.

Objective:

Evaluate the late cardiotoxicity in patients with promyelocytic leukemia treated by the PML-ATO protocol.

Methods:

An observational prospective longitudinal descriptive study was conducted of 20 patients treated with the PML-ATO protocol and followed-up in outpatient consultation from January to July 2019. More than two years had elapsed since the patients received the cardiotoxic drugs. A review was carried out of the patients' medical records and echocardiographic determination was made of left ventricular ejection fraction and overall longitudinal deformity.

Results:

Men and women presented the same frequency; mean age was 41.5 ± 11.0 years. During induction, arsenic was suspended in less than half the patients due to corrected QT elevation. In most it was only suspended for one or two days. Most patients had left ventricular ejection fraction values between 61% and 70%, whereas overall longitudinal deformity was - 24% - 22%.

Conclusions:

In the patients studied, cardiac function was not affected by the time elapsed since arsenic trioxide administration or the dose received.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )